Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294915 | 0.83 | HCAR2 (0.42) | ALDH1A1ALPLHTTSMN1; SMN2 | |
| SCHEMBL1456845 | 0.83 | HSD17B10 (0.43) | PDE4DHSD17B10CDC25BHSP90AA1CYP1A2 | |
| SCHEMBL2874155 | 0.80 | PDE4D (0.58) | PDE4DHSD17B10CDC25BCYP1A2CYP2C9 | |
| SCHEMBL1455493 | 0.79 | L3MBTL1 (0.45) | PDE4DHSD17B10HSP90AA1CYP1A2CYP2C9 | |
| SCHEMBL9941259 | 0.78 | KDM4E (0.50) | PDE4DHSD17B10CDC25BCYP1A2CYP2C9 | |
| SCHEMBL23112395 | 0.75 | KDM4E (0.48) | PDE4DHSD17B10CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12092823 | 0.75 | MAPT (0.47) | PDE4DHSD17B10CDC25BCYP1A2CYP2C9 | |
| SCHEMBL28802616 | 0.75 | CYP1A2 (0.49) | PDE4DHSD17B10CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17479555 | 0.74 | HCAR2 (0.42) | PDE4DHSD17B10CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13682657 | 0.73 | KDM4E (0.49) | PDE4DHSD17B10CDC25BCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | PDE4D 3600/4885HSD17B10 3223/4885CDC25B 3126/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PDE4D 3600/4885HSD17B10 3223/4885CDC25B 3126/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PDE4D 2673/4885HSD17B10 3449/4885CDC25B 3110/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PDE4D 2673/4885HSD17B10 3449/4885CDC25B 3110/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PDE4D 3600/4885HSD17B10 3223/4885CDC25B 3126/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | PDE4D 2673/4885HSD17B10 3449/4885CDC25B 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.